In the evolving intersection of virtual communities and real-world businesses, Shytoshi Kusama, the lead developer of Shiba Inu (CRYPTO: SHIB), has highlighted the transformative
Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding psilocybin-based TRP-8803 development’s IP.